To this regard, CAR T cells expressing both HER2 and mucin 1 showed promising results in breast cancer preclinical studies, while CAR T cells that targeted HER2 and IL-13Rα2 were more efficacious than CAR targeting only one antigen in a pre-clinical glioma model CD19/CD20. The gene discussed is ERBB2; the disease is breast cancer.